Catalyst Wire Dossier Catalyst Wire Dossier

Irinotecan hydrochloride liposome injection (Onivyde)

irinotecan liposome injection · Ipsen
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Irinotecan hydrochloride liposome injection (Onivyde), covering 2026-01-29 to 2026-01-29. Get the full timeline:

Most recent: Clinical Trial Update: Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction [Phase 2]

See pricing